IPO Year: 2023
Exchange: NASDAQ
SC 13G - CalciMedica, Inc. (0001534133) (Subject)
S-8 - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
10-Q - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
ARS - CalciMedica, Inc. (0001534133) (Filer)
DEFA14A - CalciMedica, Inc. (0001534133) (Filer)
DEF 14A - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
10-Q - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo Up to 100% reduction in hospital stays longer than 21 days Planning End-of-Phase 2 meeting with the FDA in preparation for a pivotal trial Conference call to discuss the CARPO topline results scheduled for 8:30 a.m. ET today LA JOLLA, Calif., June 27, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical c
Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT LA JOLLA, Calif. , June 26, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and raises the price target from $14 to $20.
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price target.
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the first patient has been dosed in KOURAGE, the Company's Phase 2 trial evaluating Auxora™ for the treatment of severe acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). "AKI is a serious condition, causing about 3.7 million hospitalizations annually just in the United States," said Lakhmir Chawla, M.D., Clinical Professor of Medicine at University of California San Die
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price target.
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patientsStatistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo Up to 100% reduction in hospital stays longer than 21 daysPlanning End-of-Phase 2 meeting with the FDA in preparation for a pivotal trialConference call to discuss the CARPO topline results scheduled for 8:30 a.m. ET todayLA JOLLA, Calif., June 27, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price target.
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.67) by 101.49 percent.
LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, 2024, according to preliminary lists of additions posted on Friday, May 24, 2024.
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences ("Life Bio"), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients, today announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development. Dr. Yang will be responsible for overseeing the company's research and development efforts and advancing its pipeline of cellular rejuvenation candidates. "We are delighted to welcome Dr. Yang to the Life Bio team. He brings over 20 years of experience in translational biomedical research, with expertise in research and development from drug discovery to
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
LA JOLLA, Calif., Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 7:00 a.m. ET/ 4:00 a.m. PT. A live webcast of the presentation can be accessed in th
Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.
Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif., July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the first patient has been dosed in KOURAGE, the Company's Phase 2 trial evaluating Auxora™ for the treatment of severe acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
LA JOLLA, Calif., July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at two upcoming healthcare investment conferences: H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:00am ET/ 8:00am PTJonesTrading Healthcare Seaside
LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, 2024, according to preliminary lists of additions posted on Friday, May 24, 2024.
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo Up to 100% reduction in hospital stays longer than 21 days Planning End-of-Phase 2 meeting with the FDA in preparation for a pivotal trial Conference call to discuss the CARPO topline results scheduled for 8:30 a.m. ET today LA JOLLA, Calif., June 27, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical c
Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT LA JOLLA, Calif. , June 26, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).
Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024 with data expected in 2025 Collaborators from Cedars-Sinai to present abstract on human proteomics data supporting the potential benefits of Auxora in AP at Digestive Disease Week (DDW) 2024 Cash position expected to fund operations into 2H 2025 LA JOLLA, Calif., May 13, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel in
Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week (DDW) 2024 being held May 18-21 in Washington, DC and virtually.
Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP). Auxora is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and immunologic illness
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)